Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
A. Dalbeni
Institutions:
University of Verona,
Azienda Ospedaliera Universitaria Integrata Verona
Observed institutions:
University of Verona,
Azienda Ospedaliera Universitaria Integrata Verona
ORCID:
0000-0003-0402-4176
Observed ORCID:
0000-0003-0402-4176
OpenAlex ID:
A5042639578
175P Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
2025
·
P. Lombardi
, H. Yang
, et al.
·
Annals of Oncology
·
3
PDF
Complementary evaluation of phase III immunotherapy trials in advanced HCC using the survival-inferred fragility index
2026
·
A. Dalbeni
, M. Vicardi
, et al.
·
Digestive and Liver Disease
·
2
PDF
969P Lenvatinib versus sorafenib as a second-line option in patients with unresectable hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab: An observational study
2024
·
P. Lombardi
, G.F. Manfredi
, et al.
·
Annals of Oncology
·
1
PDF
Glomerular Hyperfiltration is a new marker of fibrosis severity in non-cirrhotic NAFLD
2023
·
A. Dalbeni
, M. Garbin
, et al.
·
Digestive and Liver Disease
·
1
Author's reply: ``Survival fragility in advanced hepatocellular carcinoma immunotherapy trials requires clinical context''
2026
·
A. Dalbeni
, B. Stefanini
, et al.
·
Digestive and Liver Disease
206P Development of a machine-learning model on pre-treatment characteristics to predict long-term survivorship to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma
2025
·
F.J. Rahim
, P-C. Lee
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
162P Crossing the 3-year mark: Real-world outcomes of atezolizumab - bevacizumab for advanced HCC
2025
·
F. Tovoli
, M.A. Iavarone
, et al.
·
Annals of Oncology
PDF
Features and factors related to intensive care unit admission of cirrhotic patients with Acute-on-Chronic Liver Failure: a single-center observational study
2025
·
L. De Marco
, A. Dalbeni
, et al.
·
Digestive and Liver Disease
The changing epidemiology of patients with HCC receiving a first-line systemic therapy: insights from ARPES and ARTE databases (2008-2024)
2025
·
L. Lani
, F. Piscaglia
, et al.
·
Digestive and Liver Disease
Anticoagulation in Patients with Liver Cirrhosis and Portal Vein Thrombosis
2025
·
F. Cattazzo
, M. Bevilacqua
, et al.
·
Digestive and Liver Disease
Systolic and diastolic dysfunction, but not cardiac hyper-contractility, are unrelated to liver disease severity: a multicentric cohort study
2025
·
M. Bevilacqua
, F. Cattazzo
, et al.
·
Digestive and Liver Disease
Sorafenib as a second-line treatment after failure of atezolizumab-bevacizumab
2024
·
F. Tovoli
, M. Boe
, et al.
·
Digestive and Liver Disease
It takes a team for HCC: The adverse events reduction in first line HCC systemic therapies with the multidisciplinary ambulatory
2023
·
A. Dalbeni
, A. Auriemma
, et al.
·
Digestive and Liver Disease
Cholestatic HCV-related cryoglobulinemia: A new clinical and pathological entity
2023
·
A. Dalbeni
, S. Romeo
, et al.
·
Digestive and Liver Disease
Verona liver day: Data of liver health from the Arena
2023
·
D. Sacerdoti
, V. Paon
, et al.
·
Digestive and Liver Disease
Percutaneous Ablation of Small-HCC in Proximity with Major Vascular Structures (Perivascular HCC): Impact on Local Tumor Progression
2023
·
A. Bianco
, S. Conci
, et al.
·
HPB
PDF
Liver transplantation for hepatocellular carcinoma:outcome and prognostic factors for recurrence
2022
·
V. Paon
, I. Normelli
, et al.
·
Digestive and Liver Disease
A New Tool to Predict Success Rate of Percutaneous Ablation for HCC: The Ablation Difficulty Score
2022
·
A. Bianco
, S. Conci
, et al.
·
HPB
PDF
Show more works
View as search
Works count:
18
Citation count:
7
H-index:
2
I10-index:
Year
Topic
Type